Massive corneal edema treated with corneal cross-linking

Area of Science:

• Ophthalmology
• Corneal Disease Research
• Regenerative Medicine

Background:

• Massive corneal edema disrupts stromal architecture, causing opacity and vision loss, often necessitating corneal transplantation.
• Corneal cross-linking (CXL), a treatment for keratoconus, reduces stromal water content and compacts tissue.
• CXL's dehydrating and compacting effects suggest potential therapeutic benefits for pathologic corneal edema.

Purpose of the Study:

• To evaluate the efficacy of corneal cross-linking in managing massive corneal edema.
• To assess the impact of CXL on corneal transparency and visual acuity in edematous corneas.
• To determine if CXL can postpone or obviate the need for emergency keratoplasty.

Main Methods:

• Six patients with visually impairing corneal edema (post-surgery, post-keratoplasty, or post-infection) were treated.
• Treatments included corneal cross-linking alone or combined with amniotic membrane and/or anti-angiogenic therapy.
• Patient outcomes were assessed based on changes in corneal edema, transparency, and visual acuity.

Main Results:

• All treated patients experienced partial resolution of corneal edema.
• Significant improvements in corneal transparency and visual acuity were observed across all patients.
• Corneal cross-linking demonstrated a positive therapeutic effect on edematous corneal conditions.

Conclusions:

• Corneal cross-linking is a viable therapeutic option for managing massive corneal edema.
• CXL can improve visual acuity and corneal transparency, offering a less urgent alternative to keratoplasty.
• This treatment may allow for delayed or avoided corneal transplantation, reducing emergency surgical needs.